Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)

Launched by UNIVERSITY MEDICAL CENTER GOETTINGEN · Jul 23, 2024

Keywords

ClinConnect Summary

The MMML Predict trial is studying a new tool that can help doctors better understand how likely it is for patients with Diffuse Large B Cell Lymphoma (DLBCL) to respond to their initial treatment. This tool aims to identify patients who may be at a very high risk of treatment not working, allowing for early intervention and better care. The trial is currently looking for participants aged 18 and older who have been diagnosed with DLBCL and are set to start standard treatment. Participants must be able to give their consent and have no other active cancers or certain health issues, like active HIV.

If you join this trial, you will be part of an important effort to improve the way doctors predict treatment outcomes for DLBCL patients. You will receive standard care while contributing to research that could help many others in the future. Your participation could make a difference in how this disease is treated and understood.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histological diagnosis of DLBCL\&LBCL
• • 2. Planned treatment with guideline-based first-line therapy
• • 3. Patient's consent
• • 4. All genders, Patient age ≥ 18 years
• • 5. Ability to consent
• Exclusion Criteria:
• • 1. Treatment with R-CHOP/-like regimens already started
• • 2. Relationship of dependence/ direct employment with the investigator
• • 3. Active HIV-infection
• • 4. Presence history of other active cancers (with the exception of basal cell carcinoma of the skin)